Project ALS and Amylyx Team Up to Test Phase 2 Compound

 

Project ALS and Amylyx Pharmaceuticals are collaborating to undertake pre-clinical studies to advance the understanding of Amylyx's oral compound AMX0035 for the treatment of amyotrophic lateral sclerosis (ALS). The studies will be conducted at the Project ALS Pre-Clinical Core at Columbia University's Motor Neuron Center and will complement the company's recently initiated Phase 2 clinical program of AMX0035 for the treatment ALS. The Project ALS Pre-Clinical Core at the Columbia University's Motor Neuron Center has established a integrated and standardized platform for the testing and validation of new therapeutic strategies in recognized experimental models of ALS and for biomarker discovery. The Core, developed in collaboration with Project ALS, will accelerate the translation of new promising therapies to patients by facilitating speedy testing of new therapeutic leads discovered by laboratories studying motor neuron biology, genetics and genomics. The collaboration is an outgrowth of previous studies by The Project ALS Pre-Clinical Core at Columbia University of tauroursodeoxycholic acid (TUDCA), one of the components of AMX0035.

 

Contact Info

For advertising rates and opportunities:
Wendy Terry
Publisher
217-652-3859
wterry@bmctoday.com

About Practical Neurology

Launched in January 2002, Practical Neurology strives to enhance quality of care and improve the daily operation of neurology practices. Each month, our experts explain the real-world significance of recent advances in neurologic science and offer step-by-step advice on how to overcome the clinical and business challenges neurologists face. Our straightforward, how-to articles give neurologists tools they can put into practice right away.

 
  • BRYN MAWR COMMUNICATIONS III, LLC